Introduction
In 2019, COVID-19 emerged and was later declared as a global health crisis. The publication of the first genome sequence of SARS-CoV-2 enabled a rapid vaccine development1 and a total of 10 vaccines, including mRNA vaccines, protein subunit vaccines, inactivated vaccines and viral vector vaccines, were approved by WHO,2 three of which were available in Sweden. These included Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer), Spikevax (mRNA-1273, Moderna) and Vaxzevria (ChAdOx1 nCoV-19, Oxford-AstraZeneca). COVID-19 was initially associated with high mortality, especially in older people and in patients with comorbidities. Despite the emergence of less virulent SARS-CoV-2 variants, maximising vaccine uptake with multiple doses in the population was still of importance3,4 and achieving a high rate of vaccination in the entire population is critical to reduce hospital admissions and help healthcare systems recover.5 Vaccine hesitancy is substantial in certain populations and was reported as one of the top 10 threats to global health by the WHO in 2019.6 This hesitancy, despite differences in populations and target diseases, has been shown to be partly driven by concerns about government control, vaccine safety and vaccine effectiveness.7 In Sweden and the UK, the rates of other types of vaccination for a variety of diseases have been lower among certain ethnic groups8,9 and in areas of higher deprivation.10 This also appears to be similar for COVID-19 vaccination with lower vaccine uptake reported in several defined groups.11–13 A population study of adults ≥18 years in the UK, regarding the first-dose vaccination rates, showed lower uptake among males, minority ethnic groups, areas with higher deprivation and lower educational attainment.5 In Sweden, specifically, male sex, lower income, living alone and being born outside Sweden were all associated with a lower vaccine uptake14 as well as higher mortality from COVID-19.15 Marked differences in COVID-19 vaccination have also been noted specifically among older adults with a Swedish study reporting the lowest uptake in individuals born in low and middle-income countries (LMIC).14 Studies on COVID-19 from LMICs suggest that vaccine acceptance was driven by personal protection, while side effects were the primary cause for hesitancy.16 Booster vaccine uptake has been shown to be lower than initial vaccination with differences in individual socioeconomic factors including education and income.17 A first step is to enrol individuals into a vaccination strategy by accepting the initial vaccination, but it is also of great importance to ensure they remain in the programme for the necessary booster doses.18 The current understanding of the importance of individual sociodemographic factors vs contextual regional area surroundings in COVID-19 vaccine uptake is lacking, as is the potential driving factors that influence decisions to vaccinate or not on both the individual and contextual area level. This study aimed to investigate both individual and area, sociodemographic determinants of COVID-19 vaccine uptake among adults in a general population from Southern Sweden—first, comparing no vaccine with receiving at least two doses and then receiving the third dose (booster) with those who only had two doses.